Resveratrol may be an Effective Prophylactic Agent for Ischemic Stroke  by Zhang, Feng & Wu, Yi
J Formos Med Assoc | 2011 • Vol 110 • No 8 485
Contents lists available at ScienceDirect
Journal of the Formosan Medical Association
Journal homepage: http://www.jfma-online.com
J Formos Med Assoc 2011;110(8):485–486
Journal of the 
Formosan Medical Association
ISSN 0929 6646
Formosan Medical Association
Taipei, Taiwan
Volume 110 Number 8 August 2011
Resveratrol for prophylaxis of ischemic stroke
Microglia and chronic pain
ART in HIV-1-discordant couples in Taiwan
Prognostic evaluation of patients with multicentric papillary thyroid
 microcarcinoma
Perspectives
Resveratrol may be an Effective Prophylactic Agent for
Ischemic Stroke
Feng Zhang,1 Yi Wu2*
Stroke is a leading cause of death and disability
that places a heavy burden on society. Effective
and reliable treatments are still very limited; there-
fore, preventive clinical methods are urgently 
required.
Resveratrol (3,5,4’-trihydroxystilbene) was orig-
inally extracted from the roots of white helle-
bore. Resveratrol was initially classified as a
phytoalexin, and it was rediscovered as a cardio-
protective agent in 1992. According to epidemio-
logical studies, drinking appropriate amounts 
of wine, which contains resveratrol, can reduce
the morbidity and mortality of coronary heart
disease. Moreover, resveratrol decreases myocar-
dial ischemic reperfusion injury in acute and
chronic animal models. A series of studies has
demonstrated that resveratrol has prophylactic
and therapeutic effects for many diseases, includ-
ing cancer,1 cardiovascular diseases,2 and ischemic
injuries.2
However, these studies did not address whether
resveratrol could be an effective prophylactic agent
for ischemic stroke. Therefore, the potential of
resveratrol as a prophylactic medication should
be further studied. Hypertension, inflammation,
oxidative stress and diabetes mellitus are signi-
ficant factors for ischemic stroke; therefore, a
method that could alleviate these could be an 
effective prophylactic intervention for stroke.
First, resveratrol may regulate potent vasodila-
tors such as nitric oxide (NO),3 which could be
beneficial for hypertension patients. An experi-
ment in inducible NO synthase (NOS) knockout
mice showed that the cardioprotective effect of
resveratrol was eliminated, indicating the signifi-
cant role of NO activation induced by resvera-
trol.4 In summary, vasodilation of NO induced
by resveratrol could be beneficial for hyperten-
sion patients who have a high risk for ischemic
stroke.
Second, Resveratrol can not only inhibit the
oxidation of low-density lipoprotein, but also scav-
enge free radicals.5 A recent study has indicated
that gavage of 30 mg/kg or 100 mg/kg resveratrol
decreased superoxide production and enhanced
the inactivation of reactive oxygen species via 
reversing endothelial NOS uncoupling in mice.6
Third, the cyclooxygenase (COX) enzymes play
an important role in the generation of proinflam-
matory molecules, and inhibitors of COX enzymes
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are often used as anti-inflammatory medication.
Resveratrol can effectively inhibit COX activity 
in vivo to exert its anti-inflammatory effect. More-
over, resveratrol can dose-dependently inhibit
protein kinase Cβ, connexin 43, transforming
growth factor-β1 and COX-2, and enhance gap
junction intercellular communication, suggest-
ing that resveratrol can protect epithelial cells
against inflammation.7 Therefore, resveratrol can
exert its anti-inflammatory effect through the
above-mentioned mechanisms.
Fourth, resveratrol (5 mg/kg/day) can effec-
tively decrease the levels of blood glucose, glyco-
sylated hemoglobin, interleukin (IL)-6, tumor
necrosis factor-α, NO, IL-1β and nuclear factor-κB
p65 subunit, to rescue β cells from oxidative injury,
without influencing their function and structural
integrity.8 In addition, resveratrol (10 mg/kg and
20 mg/kg) lowers the level of p65 and IκBα and
alleviates the elevation of tumor necrosis factor-α,
IL-6 and COX-2 in diabetic rats. This confirms the
nuclear factor-κB inhibitory and anti-inflammatory
role of resveratrol, which can lead to neuropro-
tection in diabetic neuropathy, except for its an-
tioxidant effect.9 Resveratrol could alleviate the
symptoms and complications caused by diabetes,
to prevent ischemic stroke in patients with diabetes.
With regard to the clinical application of
resveratrol, in a multiple-dose study, 40 volunteers
received one dose of 25 mg, 50 mg, 100 mg or
150 mg resveratrol, or placebo, and showed no
adverse effects. Furthermore, repeated adminis-
tration of resveratrol was well-tolerated, indicat-
ing that resveratrol is safe in clinical practice.10
In summary, resveratrol could exert neuro-
protective activity against ischemic stroke, and
alleviate the risk factors for stroke by activating
multiple signaling pathways. Therefore, we spec-
ulate that resveratrol might be an effective and
reliable agent against ischemic stroke.
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